Genomic modeling of tumor onset and progression in a mouse model of aggressive human liver cancer

Carcinogenesis

Volumn 32, Issue 10, 2011, Pages 1434-1440

  Coulouarn, Cédric ^a,b   Factor, Valentina M ^a   Conner, Elizabeth A ^a   Thorgeirsson, Snorri S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITÉ DE RENNES 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; GENOME; INNATE IMMUNITY; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL; MALE; MONONUCLEAR CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENOMICS; HEPATOCYTES; HUMANS; KILLER CELLS, NATURAL; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, TRANSGENIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS C-MYC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR MARKERS, BIOLOGICAL;

EID: 80053150159     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr133     Document Type: Article

References (37)

1. El-Serag,H.B. (2004) Hepatocellular carcinoma: recent trends in the United States. Gastroenterology, 127, S27-S34.
2. Parkin,D.M. et al. (2005) Global cancer statistics, 2002. CA Cancer J. Clin., 55, 74-108.
3. Thorgeirsson,S.S. et al. (2002) Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet., 31, 339-346.
4. Lee,J.S. et al. (2004) Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology, 40, 667-676.
5. Lee,J.S. et al. (2004) Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat. Genet., 36, 1306-1311.
6. Murakami,H. et al. (1993) Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis. Cancer Res., 53, 1719-1723.
7. Jhappan,C. et al. (1990) TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell, 61, 1137-1146.
8. Santoni-Rugiu,E. et al. (1996) Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor-alpha. Am. J. Pathol., 149, 407-428.
9. Coulouarn,C. et al. (2006) Oncogene-specific gene expression signatures at preneoplastic stage in mice define distinct mechanisms of hepatocarcinogenesis. Hepatology, 44, 1003-1011.
10. Coulouarn,C. et al. (2008) Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology, 47, 2059-2067.
11. Hong,F. et al. (2002) Opposing roles of STAT1 and STAT3 in T cellmediated hepatitis: regulation by SOCS. J. Clin. Invest., 110, 1503-1513.
12. Simon,R. et al. (2007) Analysis of gene expression data using BRB-array tools. Cancer Inform., 3, 11-17.
13. Santoni-Rugiu,E. et al. (1999) Acceleration of c-myc-induced hepatocarcinogenesis by co-expression of transforming growth factor (TGF)-alpha in transgenic mice is associated with TGF-beta1 signaling disruption. Am. J. Pathol., 154, 1693-1700.
14. Deguchi,M. et al. (2002) Expression of survivin during liver regeneration. Biochem. Biophys. Res. Commun., 297, 59-64.
15. Jallepalli,P.V. et al. (2001) Securin is required for chromosomal stability in human cells. Cell, 105, 445-457.
16. Diefenbach,A. et al. (2001) Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature, 413, 165-171.
17. Zhang,J. et al. (2002) Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR. Science, 298, 422-424.
18. Waldhauer,I. et al. (2008) NK cells and cancer immunosurveillance. Oncogene, 27, 5932-5943.
19. Berzofsky,J.A. et al. (2009) The contrasting roles of NKT cells in tumor immunity. Curr. Mol. Med., 9, 667-672.
20. Swain,M.G. (2008) Hepatic NKT cells: friend or foe? Clin. Sci. (Lond), 114, 457-466.
21. Factor,V.M. et al. (1998) Disruption of redox homeostasis in the transforming growth factor-alpha/c-myc transgenic mouse model of accelerated hepatocarcinogenesis. J. Biol. Chem., 273, 15846-15853.
22. Sargent,L.M. et al. (1996) Ploidy and karyotypic alterations associated with early events in the development of hepatocarcinogenesis in transgenic mice harboring c-myc and transforming growth factor alpha transgenes. Cancer Res., 56, 2137-2142.
23. Sargent,L.M. et al. (1999) Nonrandom cytogenetic alterations in hepatocellular carcinoma from transgenic mice overexpressing c-Myc and transforming growth factor-alpha in the liver. Am. J. Pathol., 154, 1047-1055.
24. Suzuki,A. et al. (2000) Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation. Oncogene, 19, 3225-3234.
25. Belmont,L.D. et al. (1996) Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell, 84, 623-631.
26. Valdivia,M. et al. (2009) CENPA a genomic marker for centromere activity and human diseases. Curr. Genomics, 10, 326-335.
27. Chen,J. et al. (2001) MAD2B is an inhibitor of the anaphase-promoting complex. Genes Dev., 15, 1765-1770.
28. Gao,B. et al. (2008) Liver: an organ with predominant innate immunity. Hepatology, 47, 729-736.
29. Racanelli,V. et al. (2006) The liver as an immunological organ. Hepatology, 43, S54-S62.
30. Zitvogel,L. et al. (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol., 6, 715-727.
31. Aldemir,H. et al. (2005) Cutting edge: lectin-like transcript 1 is a ligand for the CD161 receptor. J. Immunol., 175, 7791-7795.
32. Nausch,N. et al. (2008) NKG2D ligands in tumor immunity. Oncogene, 27, 5944-5958.
33. Santoni-Rugiu,E. et al. (1998) Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha. Cancer Res., 58, 123-134.
34. Subleski,J.J. et al. (2009) Application of tissue-specific NK and NKT cell activity for tumor immunotherapy. J. Autoimmun., 33, 275-281.
35. Terabe,M. et al. (2000) NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol., 1, 515-520.
36. Subleski,J.J. et al. (2006) Enhanced antitumor response by divergent modulation of natural killer and natural killer T cells in the liver. Cancer Res., 66, 11005-11012.
37. Crowe,N.Y. et al. (2005) Differential antitumor immunity mediated by NKT cell subsets in vivo. J. Exp. Med., 202, 1279-1288.